Embree Financial Group lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 3.7% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 20,538 shares of the company’s stock after selling 791 shares during the quarter. Embree Financial Group’s holdings in Johnson & Johnson were worth $3,249,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of JNJ. Pathway Financial Advisors LLC lifted its holdings in shares of Johnson & Johnson by 4.3% in the 4th quarter. Pathway Financial Advisors LLC now owns 5,438 shares of the company’s stock worth $852,000 after purchasing an additional 226 shares during the last quarter. Daiwa Securities Group Inc. lifted its holdings in shares of Johnson & Johnson by 5.5% in the 4th quarter. Daiwa Securities Group Inc. now owns 297,850 shares of the company’s stock worth $46,685,000 after purchasing an additional 15,490 shares during the last quarter. OneAscent Financial Services LLC lifted its holdings in shares of Johnson & Johnson by 82.8% in the 4th quarter. OneAscent Financial Services LLC now owns 9,838 shares of the company’s stock worth $1,542,000 after purchasing an additional 4,457 shares during the last quarter. Drive Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 4.5% in the 1st quarter. Drive Wealth Management LLC now owns 9,625 shares of the company’s stock worth $1,523,000 after purchasing an additional 414 shares during the last quarter. Finally, Vestmark Advisory Solutions Inc. lifted its holdings in shares of Johnson & Johnson by 12.7% in the 4th quarter. Vestmark Advisory Solutions Inc. now owns 19,587 shares of the company’s stock worth $3,070,000 after purchasing an additional 2,201 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.
Johnson & Johnson Stock Performance
Shares of NYSE JNJ opened at $149.69 on Friday. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $360.26 billion, a price-to-earnings ratio of 9.33, a PEG ratio of 2.49 and a beta of 0.52. The stock’s fifty day simple moving average is $147.92 and its 200 day simple moving average is $153.54. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The business had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The company’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.68 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.62 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were issued a dividend of $1.24 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend was Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.31%. Johnson & Johnson’s payout ratio is currently 30.92%.
Wall Street Analysts Forecast Growth
Several brokerages recently issued reports on JNJ. Bank of America cut their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Sunday, June 30th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Monday, July 1st. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their target price for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a research note on Monday, June 17th. Eight equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $174.07.
Check Out Our Latest Stock Analysis on JNJ
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Read More
- Five stocks we like better than Johnson & Johnson
- P/E Ratio Calculation: How to Assess Stocks
- Falling Inflation Sparks Optimism for These 3 Home Builder Stocks
- What Makes a Stock a Good Dividend Stock?
- This Industrial Stock Signals a Bullish Move for Trend Followers
- EV Stocks and How to Profit from Them
- 10-for-1 Stock Split: A Game-Changer for This Bitcoin-Heavy Stock
Add to Home Screen
0 comments